Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)
Merck & Co., Inc. announced an agreement to acquire Terns Pharmaceuticals, a clinical-stage oncology company, for approximately $6.7 billion. The acquisition focuses on Terns' lead investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor, TERN-701, which is in Phase 1/2 trials for chronic myeloid leukemia (CML). The deal reflects Merck's…